The relationship between calcitonin receptor gene AluI polymorphism, bone mineral density and bone responsiveness to hormone replacement therapy in postmenopausal Korean women.
- Author:
Jung Gu KIM
1
;
Seung Yup KU
;
Byung Chul JEE
;
Chang Seok SUH
;
Seok Hyun KIM
;
Young Min CHOI
;
Shin Yong MOON
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea. kimjg@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Postmenopausal women;
Calcitonin receptor;
AluI polymorphism;
BMD;
HRT
- MeSH:
Absorptiometry, Photon;
Alkaline Phosphatase;
Bone Density*;
Calcitonin*;
Female;
Femur;
Genotype;
Hormone Replacement Therapy*;
Humans;
Immunoassay;
Osteocalcin;
Polymorphism, Restriction Fragment Length;
Receptors, Calcitonin*;
Spine
- From:Korean Journal of Obstetrics and Gynecology
2005;48(6):1476-1483
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the relationship between the calcitonin receptor (CTR) gene AluI polymorphism, serum calcitonin levels, bone mineral density (BMD) and bone responsiveness to hormone replacement therapy (HRT). METHODS: The CTR AluI polymorphism were determined by restriction fragment length polymorphism (RFLP) in 433 postmenopausal Korean women. Among these women, 306 women received sequential HRT for 1 year. Serum bone alkaline phosphatase, CrossLaps, osteocalcin and calcitonin levels were measured by immunoassay and BMD at the lumbar spine and proximal femur by dual energy X-ray absorptiometry before and after HRT of 1 year. RESULTS: The CTR genotype frequencies were 81.3% for CC, 17.5% for CT, and 1.2% for TT. No significant differences in BMD at the lumbar spine and proximal femur and their annual percentage changes after HRT were noted among CTR genotypes. There were no significant differences in the levels of calcitonin or bone turnover markers and their 6 month percentage changes after HRT among CTR genotypes. The CTR genotypes were not distributed differently between HRT-responders and HRT-nonresponders (women who lose more than 3% of bone mass per year) or between women with normal BMD and women with low bone mass. CONCLUSION: The CTR AluI polymorphism is not associated with BMD and bone responsiveness to HRT in Korean women.
